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Purpose: These investigations were undertaken to compare and contrast the roles of phosducin and phosducin-like pro­
tein in the retina.
Methods: Phosducin and phosducin-like protein were compared in an in vitro assay measuring their inhibition of transducin 
binding to light-activated rhodopsin. The two proteins were localized within the retina by immunoblot analyses and 
immunocytochemistry using affinity-purified antibodies with high specificity for each of the two homologs. The sensitiv­
ity of phosducin-like protein to phosphorylation was probed using in vitro protein kinase reactions.
Results: Phosducin and phosducin-like protein were found to have similar, though not identical, transducin inhibiting 
activity in vitro. These two proteins were found to be localized dissimilarly within the retina, with spatial overlap limited 
to the inner segments of the photoreceptors. Phosducin is found exclusively in photoreceptor cells, including the synaptic 
and nuclear layers, while phosducin-like protein is found throughout the inner retinal layers, most abundantly in the 
bipolar cells of the inner nuclear layer. Phosducin-like protein is not efficiently phosphorylated by the protein kinases 
tested, indicating that its regulation differs from that of phosducin.
Conclusions: It appears that phosducin and phosducin-like protein play distinct roles in the retina. While phosducin is 
likely to be important in feedback regulation of the visual signal, such as in light adaptation, phosducin-like protein 
probably has little if any function in the phototransduction cascade. Phosducin-like protein may have a role in regulating 
the processing of visual signals by the neural cells of the inner retina.
The visual signal transduction cascade is a prototypical 
G protein signaling pathway. Phosducin (Pd) has been identi­
fied as a potentially important regulator of this cascade [1,2]. 
Phosducin binds Gtpy with high affinity, competitively exclud­
ing the binding of Gta  and formation of the transduction-com­
petent heterotrimer [2-4]. The binding of Pd to Gtpy is regu­
lated by protein kinase A (PKA) catalyzed phosphorylation at 
Ser73 of Pd [3,5,6], and its phosphorylation state is light de­
pendent [7]. In the dark, photoreceptor cAMP concentrations 
rise due to a Ca2+/calmodulin-dependent adenylate cyclase [8], 
increasing PKA activity, resulting in a concomitant increase 
in phosphorylation of Pd. Phosphorylated Pd no longer blocks 
Gta  association with Gtpy thus more heterotrimeric transducin 
(Gt) is available for activation [9]. In the light, cytoplasmic 
Ca2+ and cAMP concentrations decrease, PKA activity drops, 
and Pd becomes dephosphorylated by cellular phosphatases 
[10]. Unphosphorylated Pd sequesters Gtpy from the Gta  sub­
unit and inhibits further activation by light-activated rhodop- 
sin (Rho*). Thus, Pd seems to play an important role in light 
and dark adaptation of photoreceptors.
Though there has been a report of Pd expression in varied 
tissues [11], it is found in abundance only in the retina and the 
developmentally related pineal gland [12]. However, a ho­
molog termed phosducin-like protein (PhLP) was shown to
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have a widespread tissue distribution [13]. Phosducin and 
PhLP are encoded by distinct genes, located on chromosomes 
1q [14] and 9 [15] in humans, respectively. Both genes ap­
pear to be alternatively spliced generating distinct splice vari­
ants [13,16]. Identity between Pd and PhLP is most extensive 
in the carboxy terminal domain. The amino terminal domain 
of Pd is seen in the crystal structure of the Pd/Gtpy complex to 
contain most of the specific Gtpy binding contacts and to oc­
cupy most of the surface to which Gta  binds [4]. Helix 1 of 
Pd, which is composed of 14 residues, includes seven resi­
dues that make specific contacts with Gtpy This segment is 
identical in Pd and PhLP except for one conservative replace­
ment. Though most of the amino acids shown to make spe­
cific contacts with Gtpy including this helix, are conserved 
between Pd and PhLP, there is some notable divergence in 
their amino terminal domains, including a nine residue inser­
tion between helices 1 and 2, and a 38 residue amino terminal 
extension, both unique to PhLP. Despite these differences, 
the conservation of key contacting sites allows PhLP to bind 
Gtpy [17]. Both Pd and PhLP have been shown to interact 
with the SUG1 subunit of the 26S proteasome, which may 
target them for degradation or possibly suggest a role in tran­
scriptional regulation through SUG1 involvement in the RNA 
polymerase II holoenzyme [18,19].
In view of the possible functional overlap between PhLP 
and Pd and the widespread distribution of PhLP, we set out to 
investigate the specific localization and the comparative roles 
of these proteins within the retina.
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METHODS
Procedures involving animals followed animal care guidelines 
of the US Public Health Service.
Assay o f  Pd/PhLP inhibition o f  Gt: The pET 15b vector 
(Novagen, Madison, WI) containing the recombinant rat Pd 
cDNA with a His6 tag was a gift from R. Gaudet (Yale Univer­
sity, see [4]). The gene encoding PhLP was cloned by reverse 
transcription/PCR from rat kidney total mRNA using RNAsin/ 
AMV RT (Promega, Madison, WI), followed by PCR ampli­
fication using the primers 5'-CAT GAC AAC CCT GGA TGA 
CAAG and 5'-TCA ATC TAT TTC TAG ATC GCT GTC TTC 
with Taq DNA polymerase (Gibco BRL, Gaithersburg, MD). 
The cDNA was then subcloned into the pET 15b vector using 
engineered NdeI and BamHI restriction sites, and transformed 
into BL-21 DE3 cells for protein expression. Recombinant 
Pd or PhLP was overexpressed in these cells and purified as 
previously described [4], except that purity was sufficient to 
obviate the need for the anion-exchange chromotography step. 
Purified His6 Pd and PhLP were buffer exchanged into iso­
tonic buffer (20 mM HEPES pH 7.5 with 100 mM KCl, 20 
mM NaCl, 2 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol 
(DTT), 0.2 mM phenylmethylsulfonyl fluoride (PMSF)) us­
ing Centricon concentrators (Millipore, Bedford, MA) and 
diluted 50% with sterile glycerol to protein concentrations in 
the range of 1 to 10 mg/ml. When prepared in this manner, 
His6 Pd and His6 PhLP can be stored at -20 °C for up to six 
months without loss of activity.
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Figure 1. Phosducin (Pd) and PhLP inhibit Gt binding to light-acti­
vated rhodopsin (Rho*). Light-induced binding of 125I-Gta  (0.2 pM) 
and GtPy (0.2 pM) to urea-stripped rod outer segment membranes 
(1.0 Rho) was carried out in the presence of Pd (green, filled 
circles) or PhLP (red, open squares) at the concentrations indicated 
(see Methods). Ovalbumin shown as negative control (blue, open 
diamonds). Error bars represent the first standard deviation of data 
from three separate experiments. 100% is 0.07-0.1 pmol of 125I- 
Gtabound/pmol of Rho*. Lines represent non-linear least squares 
fit of the data to the equation: Fraction bound = (1 - X)/(1 + [Pd]/K1/ 
2) + X, where X is the fraction remaining bound at saturating the 
concentration of Pd and K1/2 is the concentration of Pd at which half 
maximal inhibition occurred. K values were 0.37 for Pd and
0.41 for PhLP.
Urea-stripped rod outer segment membranes (UROSM), 
Gtaand Gtpy were prepared and Gtaradioiodinated as previ­
ously described [20]. Light-induced binding of Gtaand Gtpy 
to UROSM in the presence of varying concentrations of Pd or 
PhLP was performed as previously described [20]. Briefly, Pd 
or PhLP was mixed with 0.2 p,M Gta , 0.2 p,M Gtpy and non­
illuminated UROSM at 1.0 pM rhodopsin (Rho), and incu­
bated in the dark. The samples were divided in half for light 
and dark comparison. The light samples were then illumi­
nated for 1 min and all samples were centrifuged to pellet 
membranes. Supernatant aliquots were counted for 125I and 
compared to total counts determined from aliquots taken be­
fore centrifugation. Bound counts were calculated by sub­
tracting supernatant counts from total counts, and G a binding 
to Rho* was determined by subtracting dark counts from light 
counts.
Phosphorylation o f  P d and PhLP: Protein kinase A cata­
lytic subunit (2 units/pl final concentration, purified from bo­
vine heart; Fluka BioChemika, Buchs, Switzerland) was in­
cubated at 37 °C with 0.04 mg/ml recombinant Pd or PhLP in 
isotonic buffer with 1.5 mM MgCl2 and 1.5 mM ATP, includ­
ing 0.025 p,Ci/p,l 32P-ATP (NEN Life Science, Boston, MA). 
Reactions were terminated by addition of 4X SDS sample 
buffer. Samples were electrophoresed, gels stained with 
Coomassie and dried. Radioactive protein bands were quanti­
fied using a Storm 860 phosphorimager (Molecular Dynam­
ics, Sunnyvale, CA).
Protein kinase C from rat brain (Calbiochem, La Jolla, 
CA; a mixture of isoforms a, p, and y  used at a final concen­
tration of 0.002 u/pl) was incubated at 37 °C with 0.1 mg/ml 
recombinant Pd or PhLP in 20 mM Tris pH 7.5 with 10 mM 
MgCl2, 0.2 mM CaCl2, 10% (v/v) mixed micelles (mixed mi­
celles: 3% triton X-100, 3.5 mM phosphatidylserine (Avanti 
Polar-lipids, Alabaster, AL), 1 mM 1,2-didecanoyl-rac-glyc- 
erol (Calbiochem), sonicated and vortexed repeatedly), and 
10 pM ATP, including 0.025 pCi/pl 32P-ATP. Reactions were 
stopped, separated, and the phosphorylation quantified as 
above. Histone type III-S (Sigma, St. Louis, MO) was used at 
the same concentration as Pd/PhLP as a positive control.
The e isoform of PKC (Calbiochem; human recombinant, 
used at 0.003 u/pl) was incubated with 0.1 mg/ml recombi­
nant Pd or PhLP under conditions identical to those described 
above for the other PKC isoforms except lacking CaCl2. A 
peptide substrate specific for this isoform (MW 2068, 
Calbiochem) was used at 7.5 pg/ml final concentration as a 
positive control.
Affinity purification o f  antibodies: Polyclonal antibodies 
were raised against recombinant rat Pd and recombinant rat 
PhLP (see above), and also against a glutathione-S-transferase 
(GST) fusion protein incorporating the 50 amino terminal resi­
dues of PhLP (which includes the 38 residue amino terminal 
extension and 12 amino acids that are not homologous to the 
Pd sequence). This GST fusion protein was created by 
subcloning the first 150 base pairs of the human PhLP cDNA 
[21] into the pGEX-4T-3 vector using engineered BamHI and 
XhoI restriction sites and the PCR primers 5'-AGC CGG ATC 
CAT GAC CAC CCT TGA TGA TCCG and 5'-ACG CCT 
CGA GTC AGC CTG CCA GCT CAG CCT CTGC. The
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protein was expressed in BL-21 DE3 bacteria, induced with 
0.1 mM isopropyl-p-d-thiogalactopyranoside (Calbiochem), 
and harvested as with the recombinant His6 proteins above. 
Chromatography was accomplished using glutathione agar­
ose (Sigma), eluting with 20 mM reduced glutathione in 100 
mM Tris pH 8.0, on a Biologic chromatography system 
(BioRad, Hercules,CA). Three milligrams of each of these 
three proteins (Pd, PhLP, and PhLP N-terminus/GST fusion) 
were sent to HTI Bioproducts (Ramona, CA) for use as anti­
gens for polyclonal antibody production in rabbits.
Antibodies were affinity purified from the serum. Affin­
ity columns (Affi-Gel 15, BioRad) were prepared as detailed 
by the manufacturer, cross-linking either recombinant Pd or 
PhLP. The antisera were prepared for purification by incubat­
ing at 56 °C for 30 min and clarified by centrifugation at 10,000 
x g for 10 min. The supernatant was loaded on the affinity 
column which had been pre-equilibrated with 20 mM HEPES 
pH 7.5, 150 mM NaCl, and 0.2 mM PMSF and washed with 
several column volumes of this buffer. Non-specifically bound 
proteins were washed off with a high salt buffer (20 mM 
HEPES pH 7.5, 1 M NaCl, 0.2 mM PMSF). Specifically bound 
antibodies were eluted with 20 mM HEPES pH 7.5, 4 M 
MgCl2, 0.2 mM PMSF. The antibody fraction was buffer ex­
changed with 100 volumes Q2 Buffer A (20 mM HEPES pH 
7.2, 20 mM NaCl, 0.2 mM PMSF) to remove the MgCl2, con­
centrated to around 100 p,l, and further purified with a Q2 
Anion Exchange column (BioRad). The antibody eluted dur­
ing an elution gradient between 0% and 8% Q2 Buffer B (20 
mM HEPES pH 7.2, 500 mM NaCl, 0.2 mM PMSF). The 
resulting antibody peak was collected, concentrated, and the 
protein concentration determined using the Bradford/Pierce 
Coomassie method (Pierce, Rockford, IL).
Preparation o f  extracts: To quantify Pd and PhLP in tis­
sues, bovine intact rod outer segment (IROS) extracts and 
bovine retinal extracts were used. IROS was prepared by a 
method based on that of Schnetkampt et al. [22] in the dark 
using infrared illumination and image converters. Briefly, eyes 
were removed from cattle freshly killed at a local slaughter­
house and were dark adapted for 1 h at room temperature in 
HEPES/Ringer’s buffer (10 mM HEPES pH 7.5 with 120 mM 
NaCl, 3.5 mM KCl 0.2 mM CaCl2, 0.2 mM MgCl2, 0.1 mM 
EDTA, 10 mM glucose, 1 mM DTT, 0.2 mM PMSF). For 
IROS preparation, ten dissected retinas were placed into 10 
ml of retinal isolation media (20 mM Tris pH 7.4 with 600 
mM sucrose, 10 mM glucose, 1 mM CaCl2, and 5% w/v Ficoll 
400), disrupted by repeated passage through a syringe with a 
0.4 cm orifice, and the retinal mesh detained by filtration 
through cheesecloth. The filtrate was then applied to a gradi­
ent created by layering 7 ml of retinal isolation media onto an 
equal volume of 20% (w/w) sucrose, 16% (w/w) Ficoll 400, 
and the gradient was centrifuged at 27,000 rpm in a Beckman 
SW27 rotor (Beckman Instruments, Palo Alto, CA) for 1 h. 
The band containing Rho was removed and diluted with two 
volumes of retinal isolation media lacking Ficoll, and centri­
fuged at 1400 x g for 20 min. The pellet was then resuspended 
in an equal volume of retinal isolation media and stored in the 
dark at 4 °C. An aliquot was examined under the microscope 
where it was seen that 60-80% of the visible structures were 
IROS. An extract was prepared for electrophoresis by dilut­
ing IROS 1:10 with 1% SDS and triturating repeatedly through 
a 23 gauge needle. A retinal extract was also prepared by 
suspending 50 mg dark adapted bovine retina in 1 ml of 1% 
SDS, followed by repeated trituration through a 23 gauge 
needle. Total protein in the extracts was determined using the
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Figure 2. Specificity of the affinity-purified antibodies raised against phosducin and phosducin-like protein. An equal mixture of recombinant 
PhLP, Pd, and GST were electrophoresed using the amounts of protein indicated at the bottom of A-C (0.36-30 ng of each protein). Immunoblots 
were probed with anti-phosducin (A), anti-PhLP (B), and anti-PhLP N-terminus/GST fusion protein (C). See Methods for antibody details. 
Shown with the blots are graphs of immunoblot signal for Pd (filled circles, solid line interpolated) and PhLP (open squares, dotted line). 
Specificity was quantified by comparing the slopes of signals in the linear range (first three points). A. Anti-phosducin. B. Anti-PhLP. C. Anti- 
PhLP N-terminus/GST fusion protein.
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BCA assay (Pierce).
Antibody specificity: For determination of antibody speci­
ficity, an equal mixture of purified recombinant Pd, PhLP, and 
GST was prepared and varying amounts (ranging from 0.36 
to 30 ng of each protein) were electrophoresed and analyzed 
by immunoblotting as below. Primary antibodies were used 
at 1:5000 dilution.
Immunoblotting fo r  quantitation o f  Pd, PhLP, and Rho: 
Known amounts of total protein from extracts were separated 
by SDS-PAGE in 12% gels and transferred to nitrocellulose 
membranes. Membranes were blocked by incubation for 30­
60 min in 50 mM Tris pH 7.6, 150 mM NaCl, 1% tween-20 
(TBST) with 5% (w/v) nonfat dry milk. Blots were then incu­
bated overnight at 4 ° C in primary antibody (1:1000 to 1:10,000 
dilution) in TBST with 5% milk. After two 5 min washes in 
TBST, blots were incubated for 1 h at room temperature in 
secondary antibody (goat anti-rabbit IgG, heavy and light 
chain, peroxidase conjugate, Calbiochem) at 1:1000 dilution 
in TBST. Blots were then developed with the ECL Plus West­
ern detection system (Amersham Life Science, Arlington 
Heights, IL) and visualized on the phosphorimager in chemi- 
luminescence mode, for quantitation of immunoblot signals. 
Concentrations of blotted proteins were determined by com­
parison with known amounts of purified recombinant protein
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on the same blot and are reported as the average of duplicate 
determinations and the standard error of the mean.
For comparison with Rho, bleachable Rho in IROS was 
determined using the method of Bownds et al. [23]. To calcu­
late the concentration of Rho in retinal extracts, varying 
amounts of IROS and retinal extract were electrophoresed, 
blotted, and probed with the R4 anti-rhodopsin antibody (a 
gift of Dr. D. Takemoto [24]). The known concentration of 
Rho in the IROS was then used to calculate the the concentra­
tion of Rho in the retinal extract.
Immunocytochemistry: Mouse retinal sections were pre­
pared as previously described [25]. Briefly, 12 micron cry- 
ostat sections were preincubated in 10% normal goat serum in 
0.1 M phosphate buffer pH 7.4 (PB)/0.05% Triton X-100 for 
30 min. Sections were incubated 2 h at room temperature in 
primary antibody (1:100 to 1:250 dilutions in PB/0.05% Tri­
ton X -100 for anti-Pd and anti-PhLP antibodies; anti-calretinin 
antibody (Swant, Switzerland) and anti-calbindin antibody 
(Sigma) were used at manufacturers’ suggested dilutions; anti- 
recoverin antibody, a gift of Dr. J. F. McGinnis, University of 
Oklahoma, was used at 1:100 [26]). Following primary incu­
bation and PB washes, sections were incubated with fluores­
cein isothiocyanate (FITC)- or rhodamine-conjugated goat 
antirabbit IgG (Vector Laboratories, Burlingame, CA), diluted 
1:100 in PB/Triton X-100, for 1 h at room temperature. Double 
labeling was accomplished by incubation in the first primary 
followed by incubation in the FITC-conjugated secondary, re­
blocking with 10% normal goat serum, then incubating in the 
second primary followed by incubation in the rhodamine-con- 
jugated secondary. Sections were examined and images re­
corded with an inverted laser scanning confocal microscope 
(LSM510; Carl Zeiss, Oberkochen, Germany). Specificity of 
signal was determined by preincubation of antibodies with their 
respective recombinant protein (25 p.g/ml) prior to incubation 
with the tissue section.
RESULTS
Functional analysis o f  PhLP and P d in vitro: Since phosducin 
regulates G protein signals by binding to Gpy subunits [1-4] 
and it has been demonstrated that PhLP, like Pd, binds Gpy 
subunits of G proteins [17], we wished to examine the possi­
bility that PhLP is capable of regulating the visual signal. We 
previously reported the development of an in vitro assay for
Figure 3. Phosducin and PhLP in extracts of retina and intact rod 
outer segments (IROS). Bovine retina and IROS were extracted in 
1% SDS, diluted to 0.3 mg/ml total protein, and amounts indicated 
were electrophoresed and blotted (first three lanes, retinal extract; 
next three lanes, IROS extract). The last two lanes contain 0.6 and 
1.8 ng, respectively, of recombinant His6-Pd and His6-PhLP. Blots 
were probed with anti-phosducin (A) and anti-PhLP N-terminus/GST 
fusion protein antibodies (B). Quantitation of immunoblot signal 
from extract dilutions was compared with recombinant proteins to 
calculate the concentration of Pd and the concentration of PhLP with 
respect to total protein (see text). A. Anti-phosducin antibodies. B. 
Anti-PhLP N-terminus/GST fusion protein antibodies.
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Figure 4. Determination of the concentration of rhodopsin in retinal 
extract. Retinal and IROS extracts prepared as described in Figure 3. 
Total protein loads as indicated were electrophoresed and blotted (first 
three lanes, retinal extract; next three lanes, IROS extract). Blot was 
probed with anti-rhodopsin R4 antibody. Immunoblot signal was 
quantitated and the concentration of Rho in retinal extract was calcu­
lated by relating to the concentration of Rho in IROS, determined by 
photobleaching (see text). Representative of duplicate experiments.
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Pd activity based on the role of Pd in regulating the Gt medi­
ated visual signal [3]. This assay measures the ability of Pd to 
block Gt binding of activated rhodopsin (Rho*). We found 
that recombinant PhLP was equally effective as recombinant 
Pd at blocking Gt binding to Rho*, indicating stoichiometric 
binding of each to Gpy and blocking of Gt heterotrimer for­
mation (Figure 1). Half-maximal inhibition (K1/2) values were 
0.37 p,M for Pd and 0.41 p,M for PhLP. Significantly, these 
results demonstrate that PhLP and Pd have similar affinity for 
the Gp1y1 G protein isoform that is involved in the visual sig­
nal. The results shown in Figure 1 establish a need to investi­
gate whether Pd and PhLP are both present in photoreceptor 
cells and what overlap or complementarity may exist in their 
roles.
Specificity o f  antibodies: To facilitate further compari­
son between Pd and PhLP, we raised polyclonal antibodies 
directed against each of these two proteins, as well as an anti­
body directed against an N-terminal extension that is unique 
to PhLP. The specificity of these antibodies after affinity pu­
rification was tested using immunoblot analyses (Figure 2). 
Based on the curves shown in Figure 2, the anti-Pd antibody 
was 57-fold specific for Pd over PhLP. The anti-PhLP anti­
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Figure 5. Immunocytochemical localization of Pd and PhLP in mouse 
retinal sections. A. Fluorescein isothiocyanate (FITC) staining indi­
cates the localization of Pd to the photoreceptor cells, including the 
inner segments (top), outer nuclear layer (ONL), and outermost parts 
of the outer plexiform layer (OPL). C. FITC staining shows localiza­
tion of PhLP to the region near the OPL, the inner nuclear layer (INL), 
inner plexiform layer (IPL), and photoreceptor inner segments (top). 
Specificity of staining was demonstrated by competing away signal 
with preincubation of the primary antibody with 25 pg/ml recombi­
nant Pd (B) or PhLP N-terminus/GST fusion protein (D).
body bound PhLP 17-fold more avidly than it did Pd. And the 
anti-PhLP N-terminus antibody exhibited a 53-fold preference 
for PhLP over Pd. These antibodies were employed in both 
Western blots and immunocytochemistry to localize Pd and 
PhLP within the retina.
P d and PhLP in extracts o f  retina and IROS: To compare 
the relative expression levels of Pd and PhLP in whole retina 
and in dark-adapted rod outer segment preparations, bovine 
retina and intact rod outer segments (IROS) were extracted 
with 1% SDS. Protein concentrations were determined and 
increasing amounts of each were then subjected to SDS-PAGE 
and blotted along side varying loads of purified recombinant 
Pd and PhLP. Immunoblot analyses were carried out by prob­
ing with the anti-Pd and anti-PhLP N-terminus antibodies (Fig­
ure 3). By comparing the immunoblot signal in tissue bands 
to those of the recombinant proteins, it was determined that 
retina contains 0.74±0.14 ng Pd/pg total protein, whereas IROS 
contains 0.43±0.14 ng Pd/pg total protein. Retina was found 
to express 0.16±0.01 ng PhLP/pg total protein, compared with 
IROS which expresses 0.14±0.02 ng PhLP/pg total protein. 
Thus, the molar ratio of Pd:PhLP is 5.6±1.1 in retina and 
3.7±1.3 in IROS.
Figure 6. Immunolocalization of PhLP compared with that of 
calretinin, calbindin and recoverin. A. Rhodamine staining indicates 
localization of calretinin to amacrine cells (arrow) and bipolar cells 
(arrow). B. FITC staining indicates localization of PhLP in the same 
section (arrow). C. Double staining (yellow) indicates colocalization 
of calretinin and PhLP in bipolar cells but not amacrine cells (ar­
rows). D. Rhodamine staining shows localization of calbindin, re­
ported to localize to horizontal cells (arrow). E. FITC staining shows 
localization of PhLP in the same section. F. Double staining indi­
cates the lack of significant colocalization of calbindin and PhLP in 
horizontal cells (arrow). G. Rhodamine staining localizes recoverin 
to photoreceptor cells and bipolar cells (arrow). H. FITC staining 
localizes PhLP in the same section (arrow). I. Double staining shows 
colocalization of recoverin and PhLP in bipolar cells (arrow), but not 
in photoreceptor cells.
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Interestingly, there may be a difference in PhLP isoform 
expression between retinal extract and IROS extract. PhLP 
displays an anomalously slow mobility in SDS-PAGE, as does 
Pd. The apparent MW of recombinant His6-PhLP is 45 kD, 
compared to its calculated MW of 36,437. In IROS, a single 
band of apparent MW 44 kD is detected with the anti-PhLP 
(not shown) or anti-PhLP N-terminus (Figure 3B) antibodies. 
However, in retinal extract, another band of apparent MW 42 
kD is detected by these antibodies (Figure 3B). Phosducin is 
also seen as a doublet in both retinal extract and IROS (Figure 
3A). The nature of these various isoforms of PhLP and Pd is 
discussed below.
Ratio o f  P d  to Rho in IROS and retina: We examined the 
expression of Pd in relation to Rho in IROS and whole retina. 
The concentration of Rho in IROS was determined directly 
by photobleaching [23], and found to be 136±36 ng/p,g total 
protein. As direct determination of the concentration of Rho 
in retinal extract is not possible, we compared IROS and reti­
nal extracts in immunoblots using an anti-rhodopsin antibody 
(Figure 4). The concentration of Rho in retina was thus found 
to be 21.4±4.8 ng/p,g total protein. From these Rho expres­
sion values and those for Pd expression reported above, ratios 
of one Pd per 21±6 Rho molecules and one Pd per 228±96 
Rho were obtained for intact retina and IROS, respectively.
Immunocytochemical localization: Extracts of IROS are 
not completely without contamination from other cell types, 
and loss of soluble proteins such as Pd is possible. Therefore, 
this comparison with retinal extract offers only a rough esti­
mate of the comparative localization of PhLP and Pd. In or­
der to more thoroughly examine the extent of spatial overlap 
between these two proteins, we employed the affinity purified 
antibodies in immunocytochemical analyses of light-adapted 
mouse retinas. As has been previously reported [27-30], Pd 
localizes in the retina exclusively to the photoreceptor cells of 
the retina (Figure 5A). Staining is most pronounced in the 
inner segments and the synaptic regions where the photore­
ceptor cells contact the outer plexiform layer (OPL). Phosducin 
is not found in the inner layers of the retina.
Phosducin-like protein, which has previously been re­
ported to occur in a large number of tissue types [13,21], is 
found in many cells throughout the retina (Figure 5C). Sig­
nificantly, though some PhLP is seen in the outer nuclear layer 
(ONL), it is not found in great abundance in this region, where 
some Pd is localized. The most intense staining for PhLP is in 
the inner retinal layers and particularly in the inner nuclear 
layer (INL) region immediately adjacent to the OPL and in 
the inner plexiform layer (IPL). This area is populated by a 
number of different cell types. In order to more precisely de­
fine the predominant locations of PhLP, retinal sections were 
doubly stained with the anti-PhLP N-terminus antibody in con­
junction with antibodies against calretinin, calbindin, or 
recoverin (Figure 6). Calretinin has been localized to ama­
crine and ganglion cells [31], and is apparently also found in 
some bipolar cells in the mouse (see Figure 3 of Wassle et al. 
[31]). Calbindin is found in horizontal cells of the INL [31]. 
Recoverin is abundant in photoreceptor cells but is also found 
in bipolar cells [26]. As seen in Figure 6C, there is significant 
co-localization of PhLP and calretinin near the OPL, indicat­
ing that PhLP is found in some abundance in what are likely 
to be bipolar cells. Calbindin and PhLP are not significantly 
co-localized, meaning that PhLP is much less abundant in 
horizontal cells (Figure 6F). Recoverin and PhLP, however 
show significant co-localization in cells of the INL near the 
OPL (Figure 6I). Together these results show that PhLP is 
found in the INL predominantly in bipolar cells and, to a lesser 
degree, within the inner segments of photoreceptor cells.
A significant question is whether the PhLP signal in the 
inner segments confirms spatial overlap of PhLP and Pd. 
Because PhLP and Pd are homologous proteins, there is pos­
sible complication from cross-reactivity of antibodies. As 
stated above, the two antibodies in question display greater 
than 50 fold preference for their intended targets over the re­
spective homolog. Furthermore, the ratio of Pd to PhLP was 
determined to be close to one, far from the level of expression 
that would be required for significant cross-reactivity. To ana­
lyze the specificity of the immunocytochemical staining, an­
Figure 7. Specificity of PhLP immunolocalization. A. Fluorescein isothiocyanate staining shows localization of PhLP using the anti-PhLP N- 
terminus/GST fusion antibody. B. Staining in the same section is somewhat reduced overall but relative intensity of staining in the photore­
ceptor inner segments (top of panels) is maintained using antibody that has been depleted with 25 |^g/ml recombinant Pd.
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tibodies where depleted with soluble antigen, either recombi­
nant Pd or recombinant PhLP N-terminus. In both cases, deple­
tion with soluble antigen was seen to completely abolish the 
staining (Figure 5B,D), indicating that the observed staining 
results from specific recognition of these antigens. Addition­
ally, we tested the specificity of the PhLP localization by de­
pleting the anti-PhLP N-terminus antibody with recombinant 
Pd protein prior to staining with it (Figure 7). Though there 
was some overall decrease in signal, the staining in the inner 
segments was not reduced any more than that in the inner reti­
nal regions, where Pd is not found. Thus, we conclude that 
PhLP and Pd are both expressed in inner segments of light- 
adapted photoreceptors.
Divergence o f  P d  and PhLP regulation: Phosducin bind­
ing of Gpy is regulated by the phosphorylation of Pd by the 
cAMP-dependent protein kinase PKA [3,5]. We investigated 
the suitability of PhLP as a PKA substrate by comparing its 
phosphorylation in vitro with that of Pd (Figure 8A). 
Phosducin-like protein was poorly phosphorylated by PKA 
compared to Pd, the initial rate being 6-fold slower. We ob­
served the phosphorylation of a second site on Pd by PKA, as 
evidenced by the appearance of another band on SDS-PAGE. 
The kinetics of phosphorylation at this second site were still 
somewhat faster than the limited PKA phosphorylation of PhLP 
that was observed (Figure 8A).
Four consensus sites for protein kinase C (PKC) are found 
in the sequence of PhLP. We therefore tested the ability of 
PKC to phosphorylate PhLP in vitro. Compared to a standard 
PKC substrate, histone H1, PhLP was phosphorylated 250­
fold slower by PKC purified from rat brain (Figure 8B). This 
PKC is predominantly composed of isoforms a, p, and y  A 
strong consensus site for PKCe is found at residues S116GK118 
in PhLP. In vitro phosphorylation of PhLP using this PKC 
isoform was shown to be 730-fold slower than that of a spe­
cific peptide substrate (Figure 8C).
Together these results suggest that neither phosphoryla­
tion by PKA nor by PKC a , p, y  or e may be sufficiently 
robust to act as a physiologically important modulator of PhLP.
DISCUSSION
Phosducin and PhLP are highly homologous proteins that have 
both been shown to bind to the Gpy heterodimer. Since PhLP 
is widely distributed, we wished to investigate whether it is 
expressed in the same cell types within the retina as Pd, and if 
so whether it plays a redundant or complimentary role to that 
of Pd in these cells. Though the mRNA encoding PhLP has 
previously been found in retinal tissue [32], analysis of PhLP 
protein expression in this tissue had not been performed. Our 
results show that PhLP, like Pd, binds G(py inhibiting its asso­
ciation with Gta  on Rho*, and that it is expressed in several 
cell types in the retina, including some expression in the pho­
toreceptor cells.
Phosducin is believed to play an important role in regula­
tion of the visual signal in photoreceptor cells, where it is abun­
dantly expressed [1-3]. We previously reported that Pd was 
expressed in IROS at a Rho to Pd ratio of 16:1 [33]. This 
level of expression is similar to that of Gt, which has a Rho to 
Gt ratio of approximately 10:1 in rods [34-36]. From these 
data, we concluded that there is sufficient Pd in the rod to 
bind to a majority of the Gtpy [33]. In contrast, here we have 
found a significantly higher Rho to Pd ratio of about 300:1 in 
IROS. The reason for the discrepancy may be the amount of 
inner segment that detaches with the outer segment in the bo­
vine IROS preparation, which depends on the force used to 
shear the rod outer segments from the retina. Since most of 
the Pd in the rod localizes to the inner segment ([27-30] and 
Figure 5A), the Rho to Pd ratio will depend on the amount of 
inner segment in the IROS preparation. To avoid this ambi­
guity, we determined the ratio of Rho to Pd in the intact retina, 
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Figure 8. Phosphorylation of PhLP by PKA and PKC isoforms. Phosphorylation of PhLP, Pd, histone and peptide substrates by PKA and PKC 
isoforms. Phosphorylation conditions are specified in Methods. Error bars represent standard deviation of duplicate or triplicate samples. A. 
Protein kinase A catalytic subunit was used to phosphorylate purified recombinant Pd or PhLP in vitro and the 32P incorporated determined by 
phosphorimager analysis of SDS gels. The relative amount of phosphorylation is shown for the high-efficiency site that has been shown to be 
Ser73 of Pd (filled circles), for a second less efficient site on Pd which results in the appearance of a second band (open squares), and for PhLP 
(open diamonds). B. Protein kinase C from rat brain (a mixture of isoforms a, p, and y) was used to phosphorylate a standard substrate 
(histone, filled circles) and recombinant PhLP (open squares). C. Recombinant protein kinase Ce was used to phosphorylate a peptide sub­
strate (filled circles) and recombinant PhLP (open squares).
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This ratio was determined to be about 20:1. Since Pd is ex­
pressed exclusively in photoreceptor cells (Figure 5A), and 
primarily in rods over cones [30], this retinal ratio should re­
flect Pd expression in the rods. Thus, the current data also 
support the notion that Pd and transducin are expressed at simi­
lar levels in intact rods.
The fact that Pd is found primarily in the inner segment 
raises questions concerning the accessibility of Pd to transducin 
pYin the outer segment. Because it is a soluble, cytosolic pro­
tein, Pd may translocate between the inner and outer segment 
depending on the signaling state of the rod. In fact, 
immunolocalization experiments in dark and light-adapted 
retina have shown translocation of Pd in a light-dependent 
manner, moving from the outer segment in dark-adapted retina 
to the inner segment and ONL in light-adapted retina [28,29]. 
Our light-adapted retina data show localization to the inner 
parts of the photoreceptor cells, in agreement with these re­
ports (see Figure 5A).
Transducin p subunit has been shown to exhibit a similar 
light-dependent localization to Pd, being found in the synap­
tic, nuclear, and inner segment regions of photoreceptors in 
the light and exclusively in the outer segments in the dark 
[28]. Since Pd is phosphorylated in the dark [7], it presum­
ably is not bound to G(py in the outer segments. Colocalization 
of Pd and Gtpy in the inner regions of photoreceptor cells in 
the light is not surprising, since these proteins are known to 
be associated under these conditions [1]. It is significant that 
in our light-adapted retinal sections, PhLP is not seen in high 
abundance in the ONL where the majority of the G(py signal 
has been found [28], suggesting that if PhLP does bind G(py 
in the photoreceptors, it involves only the limited subpopula­
tion of G(py that is localized to the inner segments. The se­
questration of G(py away from the outer segments in the light 
may be important as an additional way of dampening sensi­
tivity, in combination with its inactivation due to Pd binding. 
The transducin alpha subunit has been localized to the outer 
segments at night, translocating to the inner segments and ONL 
during the day [37] in parallel with the light-dependent trans­
location of both Gtpy and Pd. However, it must be recognized 
that the translocations referred to are deduced from immuno- 
cytochemical localizations, and the possibility of light- de­
pendent masking of antibody epitopes must be taken into ac­
count in interpreting such results.
In whole retinal extracts, anti-PhLP antibodies detect two 
bands, only one of which is seen in IROS preparations (Fig­
ure 3B). Miles et al. [13] initially reported two different 
isoforms of PhLP predicted from cDNA’s cloned from rat brain. 
The Miles et al. long form (PhLPL) corresponds to full length 
PhLP (see genbank entry L15354 for correct N-terminal se­
quence). These authors also reported a short form (PhLPS) that 
begins at PhLP residue Met78 but is otherwise identical to PhLPL 
[13]. The 42 kD band of PhLP that we see in retina cannot be 
equivalent to PhLPS because it is recognized by the anti-PhLP 
N-terminus antibody, which is directed against the first 50 
amino acids of PhLP. This 42 kD band does not correspond to 
any of the forms of Pd family members proposed by Craft et 
al. [16], again because they would not be recognized with this 
antibody. Interestingly, the antibody directed against full-
length PhLP did not detect any PhLP bands other than the two 
observed with the anti-PhLP N-terminus antibody (data not 
shown). The 42 kD band may represent a novel isoform of 
PhLP or may simply be a proteolytic product of the full length 
protein produced in the extraction.
Phosducin is seen as a doublet in both retinal and IROS 
extracts (Figure 3A). We note the appearance of a doublet of 
Pd upon hyperphosphorylation by PKA in vitro (data not 
shown). It is possible that the doublet of Pd seen in the in 
vivo extracts represents two different states of posttranslational 
modification.
Within the inner retina, we find that PhLP is abundant in 
bipolar cells (see Figure 6C, I). This finding may be signifi­
cant in view of the importance of G protein signaling in these 
cells. Nawy and Jahr [38] showed that glutamate activation of 
its receptor in depolarizing bipolar cells (also called on-center 
bipolar cells or ON-bipolar cells) suppresses cGMP-depen- 
dent conductance, via signaling that they hypothesized to be 
very similar to the pathway of photoreceptor light transduc­
tion [39]. On-center bipolar cells are excited when the photo­
receptor to which they are postsynaptically connected hyper- 
polarizes, and in turn they stimulate on-center ganglion cells 
and inhibit off-center ganglion cells. This excitation of the 
bipolar cell results from the reduction in glutamate that is trans­
mitted across the synapse during the dark current in the pho­
toreceptor. A decrease in glutamate decreases the stimulation 
of its receptor. This decrease in receptor stimulation has been 
thought to lead to decreased bipolar PDE activity, accumula­
tion of cGMP, and the opening of cGMP-dependent channels 
causing depolarization [40]. More recently, however, Nawy 
[41] has shown that PDE is not involved in salamander bipo­
lar cell signaling. Nonetheless, a G protein pathway seems to 
be important in bipolar cells, transducing the signal from the 
glutamate neurotransmitter. Immunocytochemical analyses 
showed that while transducin is not present in bipolar cells, 
G0a  is [42,43]. The human metabotropic glutamate receptor 
type 6 was cloned from retina and found to be expressed in 
bipolar cells [44]; and this receptor was found to functionally 
couple to transducin and (more efficiently) to G0 in an in vitro 
system [45]. Nawy has recently reported data consistent with 
the involvement of G0 but not Gi or Gt in bipolar cell transduc­
tion [41]. Thus, PhLP may regulate G0 activity in this trans­
duction pathway.
In these experiments, we show that while largely dispar­
ate in their localization, Pd and PhLP are both found in the 
inner segments of light adapted photoreceptors (see Figure 5). 
It is doubtful that one of these dominates in cones and the 
other in rods, as both seem equally distributed within this layer. 
von Schantz et al. [30] showed that Pd is found primarily in 
rods but not in the most abundant cones in ground squirrels. 
We found that there was not significant colocalization of PhLP 
and peanut agglutinin, which specifically stains cones (data 
not shown). Thus we conclude that PhLP and Pd probably do 
overlap within rod photoreceptors. Importantly, in these light- 
adapted cells, Pd is found in the nuclear and synaptic region 
of the cells as well as the inner segments, whereas PhLP is 
less abundant and more localized to the inner segments.
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Where these two proteins do occur together, differences 
in their regulation would be of great interest. The PKA-de- 
pendent regulation of Pd binding to Gtpy is significant be­
cause it allows feedback regulation of the sensitivity of the 
visual signal [3,8]. The PhLP sequence G117KMTLK122 is ho­
mologous to R70KMS73, the PKA-phosphorylated regulatory 
site in Pd, and fits the PKC substrate consensus; however it 
was not efficiently phosphorylated by the a , p, y, or e isoforms 
of this kinase (see Figure 7B,C). Though residues K89KLS92of 
PhLP constitute a possible PKA site, we have shown that PKA 
does not phosphorylate PhLP as efficiently as it does Pd; not­
ing that PhLP is phosphorylated by this enzyme with kinetics 
even slower than those seen for phosphorylation of a second 
site (not the Ser73 site) in Pd (see Figure 7A). This observa­
tion leads us to conclude that the regulatory role of this phos­
phorylation is questionable. It is possible that PhLP is regu­
lated by phosphorylation by some kinase other than PKA or 
PKC, or is regulated in some other way. Lazarov et al. [21] 
report regulation of PhLP mRNA stability by elements con­
tained within the 3' untranslated region, but these do not ad­
dress the regulation of the translated gene product that we show 
to coexist with Pd in the same subcellular location within pho­
toreceptors. Further work to determine how PhLP is regulated 
is necessary before a complete understanding of the divergent 
roles of Pd and PhLP can be achieved.
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